Centre Hospitalier Universitaire Vaudois
chuv.chLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
205
Active
40
Phase 3
5
Total enrollment
13,360,412
Pipeline matrix
Showing 26 of 26 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Dosage Adjustment Rules for Augmented Renal Clearance (DAR-ARC) for piperacillin-tazobactam and meropenem | — | — | — | — | — | 1 | |
| Standard dosages of piperacillin-tazobactam or meropenem | — | — | — | — | — | 1 | |
| Immunonutrition | — | — | — | — | — | 1 | |
| Bevacizumab | — | — | — | — | — | 2 | |
| Apixaban 5 MG [Eliquis] | — | — | — | — | — | 1 | |
| Edoxaban 60 MG [Lixiana] | — | — | — | — | — | 1 | |
| Patent blue V dye | — | — | — | — | — | 1 | |
| Indocyanine green dye | — | — | — | — | — | 1 | |
| Trimipramine | — | — | — | — | — | 1 | |
| Cohort 1: Atezolizumab | — | — | — | — | — | 1 | |
| Cohort 2: Atezolizumab | — | — | — | — | — | 1 | |
| Cohort 2: Bevacizumab | — | — | — | — | — | 1 | |
| Sodium lactate | — | — | — | — | — | 1 | |
| CMP-001 | — | — | — | — | — | 1 | |
| Autologous Dendritic Cell Vaccine Loaded with Personalized Peptides | — | — | — | — | — | 2 | |
| Low dose cyclophosphamide | — | — | — | — | 2 | ||
| Cyclophosphamide | — | — | — | — | — | 3 | |
| Fludarabine | — | — | — | — | — | 3 | |
| Interleukin-2 | — | — | — | — | — | 3 | |
| NeoTIL | — | — | — | — | — | 1 | |
| NY-ESO-1 TCR redirected autologous T cell product | — | — | — | — | — | 1 | |
| Non-myeloablative lymphodepleting chemotherapy | — | — | — | — | — | 1 | |
| Morphine provided via oral PCA | — | — | — | — | — | 2 | |
| Morphine provided via oral PCA + morphine administered at a scheduled regimen | — | — | — | — | — | 2 | |
| Pericapsular nerve group (PENG) block with 0.75% ropivacaine guided by ultrasound | — | — | — | — | — | 1 | |
| Femoral, sciatic and lateral femoral cutaneous nerve block with 0.375% ropivacaine | — | — | — | — | — | 1 |
Next readouts
- 2025-12
- 2026-03
- 2026-06
- 2026-08
- 2027-03
- 2027-06
- 2027-09
- 2027-09
- 2027-09-01
- 2027-11
Top conditions
- Analgesia5
- Postoperative Pain5
- Obstructive Sleep Apnea4
- End Stage Renal Disease4
- Melanoma4
- Posttraumatic Stress Disorder4
- Ischemic Stroke3
- Solid Tumor, Adult3
Frequently asked questions about Centre Hospitalier Universitaire Vaudois
- How many clinical trials does Centre Hospitalier Universitaire Vaudois have on ClinicalTrials.gov?
- Centre Hospitalier Universitaire Vaudois is listed as the lead sponsor on 205 clinical trials in ClinicalTrials.gov, 40 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Centre Hospitalier Universitaire Vaudois's trials are in Phase 3?
- 5 of Centre Hospitalier Universitaire Vaudois's trials are in Phase 3, spread across 26 active drug programs.
- What therapeutic areas does Centre Hospitalier Universitaire Vaudois focus on?
- Centre Hospitalier Universitaire Vaudois's most-studied conditions on ClinicalTrials.gov are Analgesia, Postoperative Pain, Obstructive Sleep Apnea, End Stage Renal Disease, Melanoma.
- When are Centre Hospitalier Universitaire Vaudois's next clinical trial readouts?
- Centre Hospitalier Universitaire Vaudois has 10 upcoming primary-completion readouts tracked here; the soonest is “CMP-001 and Pre-operative Stereotactic Body Radiation Therapy (SBRT) in Early Stage Triple Negative Breast Cancer (TNBC)”, expected around 2025-12.